Maze Therapeutics, Inc. (MAZE)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGM
27.48 USD
+1.25
(4.766%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 3:40 a.m. EDT
The investment case for Maze Therapeutics is currently defined by a stark disconnect between optimistic analyst targets and deteriorating market reality. While analysts project a mean price of $61.50, the stock has lost nearly half its value over the last year, trading near its 52-week low. This divergence suggests the market has already priced out the company's risks, rendering the high valuation multiples unjustifiable given the negative earnings and cash burn. Fundamentally, the business faces severe headwinds. With negative earnings, negative free cash flow, and a massive operating loss, the company is burning through capital without generating revenue. The balance sheet, while showing a high current ratio due to cash reserves, is fragile in a biotech context where cash burn rates dictate survival timelines. The lack of a dividend and negative returns on equity confirm that the company is not yet a mature income generator. Technically and sentiment-wise, the outlook is grim. The stock is trading below both its 50-day and 200-day moving averages, confirming a downtrend. More alarmingly, options activity reveals a 'bearish put spread' mentality; traders are buying insurance at lower strikes rather than betting on upside moves. This heavy put positioning acts as a self-fulfilling prophecy, capping rallies and accelerating declines if bad news emerges. Until the company demonstrates a path to profitability or a catalyst that shifts the options flow from protection to speculation, the risk-reward profile remains heavily skewed against investors. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.058581 |
| AutoETS | 0.059578 |
| AutoARIMA | 0.059578 |
| AutoTheta | 0.094073 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 0.42 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.455 |
| Excess Kurtosis | -0.04 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 13.335 |
| Revenue per Share | 0.377 |
| Market Cap | 1,526,491,136 |
| Forward P/E | -8.52 |
| Website | https://www.mazetx.com |
As of Oct. 10, 2026, 3:40 a.m. EDT: Speculators are positioning for a significant downside event rather than a rally. Put open interest is heavily concentrated at strikes below the current price (15, 17.5, 25), creating a dense wall of protection. Conversely, call activity is sparse and skewed toward distant strikes (35, 40, 45) with very low volume relative to open interest, indicating a lack of immediate bullish conviction. The implied volatility structure shows elevated premiums for downside protection compared to upside speculation, suggesting the market is pricing in a 'sell-off' scenario rather than a breakout.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.011866212 |
| Address1 | 171 Oyster Point Blvd |
| Address2 | Suite 300 |
| All Time High | 53.65 |
| All Time Low | 6.71 |
| Ask | 35.55 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 773,030 |
| Average Daily Volume3 Month | 584,357 |
| Average Volume | 584,357 |
| Average Volume10Days | 773,030 |
| Bid | 19.91 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 8.164 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 27.48 |
| Current Ratio | 18.31 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 28.105 |
| Day Low | 26.46 |
| Debt To Equity | 13.335 |
| Display Name | Maze Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -143,707,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -8.182 |
| Enterprise To Revenue | 58.791 |
| Enterprise Value | 1,175,827,200 |
| Eps Current Year | -2.73942 |
| Eps Forward | -3.22374 |
| Eps Trailing Twelve Months | -2.48 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 26.8288 |
| Fifty Day Average Change | 0.65119934 |
| Fifty Day Average Change Percent | 0.024272399 |
| Fifty Two Week Change Percent | -1.1866212 |
| Fifty Two Week High | 53.65 |
| Fifty Two Week High Change | -26.170002 |
| Fifty Two Week High Change Percent | -0.48779127 |
| Fifty Two Week Low | 21.95 |
| Fifty Two Week Low Change | 5.529999 |
| Fifty Two Week Low Change Percent | 0.25193617 |
| Fifty Two Week Range | 21.95 - 53.65 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,738,333,800,000 |
| Float Shares | 36,796,880 |
| Forward Eps | -3.22374 |
| Forward P E | -8.5242605 |
| Free Cashflow | -63,627,624 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 141 |
| Fullday Change | 0.87000084 |
| Fullday Change Percent | 3.316816 |
| Fullday Price | 27.48 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 1.0 |
| Gross Profits | 20,000,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.015310001 |
| Held Percent Institutions | 1.06878 |
| Implied Shares Outstanding | 55,549,168 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,025-01-31 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California. |
| Long Name | Maze Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 1,526,491,136 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_602685968 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -133,590,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,558,154,162 |
| Number Of Analyst Opinions | 12 |
| Open | 26.59 |
| Operating Cashflow | -106,538,000 |
| Operating Margins | -7.2806 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 650 850 5070 |
| Previous Close | 26.23 |
| Price Eps Current Year | -10.031321 |
| Price Hint | 2 |
| Price To Book | 3.365997 |
| Price To Sales Trailing12 Months | 76.324554 |
| Profit Margins | 0.0 |
| Quick Ratio | 18.026 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.07692 |
| Region | US |
| Regular Market Change | 1.25 |
| Regular Market Change Percent | 4.76554 |
| Regular Market Day High | 28.105 |
| Regular Market Day Low | 26.46 |
| Regular Market Day Range | 26.46 - 28.105 |
| Regular Market Open | 26.59 |
| Regular Market Previous Close | 26.23 |
| Regular Market Price | 27.48 |
| Regular Market Time | 1,792,094,401 |
| Regular Market Volume | 539,300 |
| Return On Assets | -0.21794 |
| Return On Equity | -0.37348998 |
| Revenue Per Share | 0.377 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 55,549,168 |
| Shares Percent Shares Out | 0.1182 |
| Shares Short | 6,565,330 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 5,918,321 |
| Short Name | Maze Therapeutics, Inc. |
| Short Percent Of Float | 0.1331 |
| Short Ratio | 7.94 |
| Source Interval | 15 |
| State | CA |
| Symbol | MAZE |
| Target High Price | 110.0 |
| Target Low Price | 46.0 |
| Target Mean Price | 61.5 |
| Target Median Price | 54.0 |
| Total Cash | 411,087,008 |
| Total Cash Per Share | 7.4 |
| Total Debt | 60,423,000 |
| Total Revenue | 20,000,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.48 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 32.338425 |
| Two Hundred Day Average Change | -4.858425 |
| Two Hundred Day Average Change Percent | -0.15023692 |
| Type Disp | Equity |
| Volume | 539,300 |
| Website | https://www.mazetx.com |
| Zip | 94,080 |